Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle

Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of the SARS-CoV-2 receptor-binding domain (RBD) of the spike glycoprotein (S) fused to a huma...

Full description

Saved in:
Bibliographic Details
Published inVaccines (Basel) Vol. 9; no. 11; p. 1347
Main Authors Royal, Joshua M., Simpson, Carrie A., McCormick, Alison A., Phillips, Amanda, Hume, Steve, Morton, Josh, Shepherd, John, Oh, Youngjun, Swope, Kelsi, DeBeauchamp, Jennifer L., Webby, Richard J., Cross, Robert W., Borisevich, Viktoriya, Geisbert, Thomas W., Demarco, Jennifer K., Bratcher, Barry, Haydon, Hugh, Pogue, Gregory P.
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 17.11.2021
MDPI
Subjects
ACE2
Angiotensin-converting enzyme 2
Antigens
Binding
Chromatography
Coronaviruses
COVID-19
COVID-19 vaccines
CpG islands
Disease transmission
Epitopes
Fatalities
Glycoproteins
Humidity
Immunogenicity
Immunoglobulin G
Infections
Influenza
Lymphocytes T
Manufacturing
Monoclonal antibodies
nanoparticle
Nanoparticles
Neutralizing
Pandemics
Pathogens
Peptides
plant-based manufacturing
Proteins
receptor-binding domain
Receptors
Respiratory diseases
SARS-CoV-2 vaccine
Severe acute respiratory syndrome coronavirus 2
Spike glycoprotein
Spike protein
Tobacco
Transmission electron microscopy
Vaccines
Viral diseases
Viruses
United States > US
Online AccessGet full text

Cover

Abstract Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of the SARS-CoV-2 receptor-binding domain (RBD) of the spike glycoprotein (S) fused to a human IgG1 Fc domain (CoV-RBD121) and conjugated to a modified tobacco mosaic virus (TMV) nanoparticle. In vitro, CoV-RBD121 bound to the host virus receptor ACE2 and to the monoclonal antibody CR3022, a neutralizing antibody that blocks S binding to ACE2. The CoV-RBD121-NP vaccine candidate retained key SARS-CoV-2 spike protein epitopes, had consistent manufacturing release properties of safety, identity, and strength, and displayed stable potency when stored for 12 months at 2–8 °C or 22–28 °C. Immunogenicity studies revealed strong antibody responses in C57BL/6 mice with non-adjuvanted or adjuvanted (7909 CpG) formulations. The non-adjuvanted vaccine induced a balanced Th1/Th2 response and antibodies that recognized both the S1 domain and full S protein from SARS2-CoV-2, whereas the adjuvanted vaccine induced a Th1-biased response. Both adjuvanted and non-adjuvanted vaccines induced virus neutralizing titers as measured by three different assays. Collectively, these data showed the production of a stable candidate vaccine for COVID-19 through the association of the SARS-CoV-2 RBD with the TMV-like nanoparticle.
AbstractList Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of the SARS-CoV-2 receptor-binding domain (RBD) of the spike glycoprotein (S) fused to a human IgG1 Fc domain (CoV-RBD121) and conjugated to a modified tobacco mosaic virus (TMV) nanoparticle. In vitro, CoV-RBD121 bound to the host virus receptor ACE2 and to the monoclonal antibody CR3022, a neutralizing antibody that blocks S binding to ACE2. The CoV-RBD121-NP vaccine candidate retained key SARS-CoV-2 spike protein epitopes, had consistent manufacturing release properties of safety, identity, and strength, and displayed stable potency when stored for 12 months at 2–8 °C or 22–28 °C. Immunogenicity studies revealed strong antibody responses in C57BL/6 mice with non-adjuvanted or adjuvanted (7909 CpG) formulations. The non-adjuvanted vaccine induced a balanced Th1/Th2 response and antibodies that recognized both the S1 domain and full S protein from SARS2-CoV-2, whereas the adjuvanted vaccine induced a Th1-biased response. Both adjuvanted and non-adjuvanted vaccines induced virus neutralizing titers as measured by three different assays. Collectively, these data showed the production of a stable candidate vaccine for COVID-19 through the association of the SARS-CoV-2 RBD with the TMV-like nanoparticle.
Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of the SARS-CoV-2 receptor-binding domain (RBD) of the spike glycoprotein (S) fused to a human IgG1 Fc domain (CoV-RBD121) and conjugated to a modified tobacco mosaic virus (TMV) nanoparticle. In vitro, CoV-RBD121 bound to the host virus receptor ACE2 and to the monoclonal antibody CR3022, a neutralizing antibody that blocks S binding to ACE2. The CoV-RBD121-NP vaccine candidate retained key SARS-CoV-2 spike protein epitopes, had consistent manufacturing release properties of safety, identity, and strength, and displayed stable potency when stored for 12 months at 2-8 °C or 22-28 °C. Immunogenicity studies revealed strong antibody responses in C57BL/6 mice with non-adjuvanted or adjuvanted (7909 CpG) formulations. The non-adjuvanted vaccine induced a balanced Th1/Th2 response and antibodies that recognized both the S1 domain and full S protein from SARS2-CoV-2, whereas the adjuvanted vaccine induced a Th1-biased response. Both adjuvanted and non-adjuvanted vaccines induced virus neutralizing titers as measured by three different assays. Collectively, these data showed the production of a stable candidate vaccine for COVID-19 through the association of the SARS-CoV-2 RBD with the TMV-like nanoparticle.Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a vaccine candidate CoV-RBD121-NP, which is comprised of the SARS-CoV-2 receptor-binding domain (RBD) of the spike glycoprotein (S) fused to a human IgG1 Fc domain (CoV-RBD121) and conjugated to a modified tobacco mosaic virus (TMV) nanoparticle. In vitro, CoV-RBD121 bound to the host virus receptor ACE2 and to the monoclonal antibody CR3022, a neutralizing antibody that blocks S binding to ACE2. The CoV-RBD121-NP vaccine candidate retained key SARS-CoV-2 spike protein epitopes, had consistent manufacturing release properties of safety, identity, and strength, and displayed stable potency when stored for 12 months at 2-8 °C or 22-28 °C. Immunogenicity studies revealed strong antibody responses in C57BL/6 mice with non-adjuvanted or adjuvanted (7909 CpG) formulations. The non-adjuvanted vaccine induced a balanced Th1/Th2 response and antibodies that recognized both the S1 domain and full S protein from SARS2-CoV-2, whereas the adjuvanted vaccine induced a Th1-biased response. Both adjuvanted and non-adjuvanted vaccines induced virus neutralizing titers as measured by three different assays. Collectively, these data showed the production of a stable candidate vaccine for COVID-19 through the association of the SARS-CoV-2 RBD with the TMV-like nanoparticle.
Author Demarco, Jennifer K.
Borisevich, Viktoriya
Shepherd, John
Pogue, Gregory P.
Webby, Richard J.
Hume, Steve
Morton, Josh
Phillips, Amanda
McCormick, Alison A.
Swope, Kelsi
Royal, Joshua M.
Oh, Youngjun
Bratcher, Barry
Simpson, Carrie A.
Geisbert, Thomas W.
Cross, Robert W.
DeBeauchamp, Jennifer L.
Haydon, Hugh
AuthorAffiliation 3 Department of Infectious Disease, St. Jude Children’s Hospital, Memphis, TN 38105, USA; Jennifer.DeBeauchamp@stjude.org (J.L.D.); richard.webby@stjude.org (R.J.W.)
2 Department of Biological & Pharmaceutical Sciences, Touro University California, Vallejo, CA 95688, USA; amccormi@touro.edu
4 Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA; rwcross@UTMB.EDU (R.W.C.); viborise@utmb.edu (V.B.); twgeisbe@utmb.edu (T.W.G.)
6 IC² Institute, University of Texas at Austin, Austin, TX 78805, USA
5 Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY 40202, USA; jennifer.wolf.2@louisville.edu
1 Kentucky BioProcessing, Inc., Owensboro, KY 42301, USA; simpsoc3@kentuckybioprocessing.com (C.A.S.); phillia2@kentuckybioprocessing.com (A.P.); humes@kentuckybioprocessing.com (S.H.); mortonj2@kentuckybioprocessing.com (J.M.); shephej@ke
AuthorAffiliation_xml – name: 2 Department of Biological & Pharmaceutical Sciences, Touro University California, Vallejo, CA 95688, USA; amccormi@touro.edu
– name: 6 IC² Institute, University of Texas at Austin, Austin, TX 78805, USA
– name: 1 Kentucky BioProcessing, Inc., Owensboro, KY 42301, USA; simpsoc3@kentuckybioprocessing.com (C.A.S.); phillia2@kentuckybioprocessing.com (A.P.); humes@kentuckybioprocessing.com (S.H.); mortonj2@kentuckybioprocessing.com (J.M.); shephej@kentuckybioprocessing.com (J.S.); ohy@kentuckybioprocessing.com (Y.O.); swopek@kentuckybioprocessing.com (K.S.); bratchb1@rjrt.com (B.B.); haydonh@kentuckybioprocessing.com (H.H.); pogueg1@RJRT.com (G.P.P.)
– name: 3 Department of Infectious Disease, St. Jude Children’s Hospital, Memphis, TN 38105, USA; Jennifer.DeBeauchamp@stjude.org (J.L.D.); richard.webby@stjude.org (R.J.W.)
– name: 4 Galveston National Laboratory, Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77550, USA; rwcross@UTMB.EDU (R.W.C.); viborise@utmb.edu (V.B.); twgeisbe@utmb.edu (T.W.G.)
– name: 5 Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, School of Medicine, University of Louisville, Louisville, KY 40202, USA; jennifer.wolf.2@louisville.edu
Author_xml – sequence: 1
  givenname: Joshua M.
  orcidid: 0000-0002-4243-2667
  surname: Royal
  fullname: Royal, Joshua M.
– sequence: 2
  givenname: Carrie A.
  surname: Simpson
  fullname: Simpson, Carrie A.
– sequence: 3
  givenname: Alison A.
  surname: McCormick
  fullname: McCormick, Alison A.
– sequence: 4
  givenname: Amanda
  surname: Phillips
  fullname: Phillips, Amanda
– sequence: 5
  givenname: Steve
  surname: Hume
  fullname: Hume, Steve
– sequence: 6
  givenname: Josh
  surname: Morton
  fullname: Morton, Josh
– sequence: 7
  givenname: John
  surname: Shepherd
  fullname: Shepherd, John
– sequence: 8
  givenname: Youngjun
  surname: Oh
  fullname: Oh, Youngjun
– sequence: 9
  givenname: Kelsi
  orcidid: 0000-0003-1085-0319
  surname: Swope
  fullname: Swope, Kelsi
– sequence: 10
  givenname: Jennifer L.
  surname: DeBeauchamp
  fullname: DeBeauchamp, Jennifer L.
– sequence: 11
  givenname: Richard J.
  orcidid: 0000-0002-4397-7132
  surname: Webby
  fullname: Webby, Richard J.
– sequence: 12
  givenname: Robert W.
  orcidid: 0000-0001-7718-1522
  surname: Cross
  fullname: Cross, Robert W.
– sequence: 13
  givenname: Viktoriya
  surname: Borisevich
  fullname: Borisevich, Viktoriya
– sequence: 14
  givenname: Thomas W.
  surname: Geisbert
  fullname: Geisbert, Thomas W.
– sequence: 15
  givenname: Jennifer K.
  surname: Demarco
  fullname: Demarco, Jennifer K.
– sequence: 16
  givenname: Barry
  surname: Bratcher
  fullname: Bratcher, Barry
– sequence: 17
  givenname: Hugh
  surname: Haydon
  fullname: Haydon, Hugh
– sequence: 18
  givenname: Gregory P.
  surname: Pogue
  fullname: Pogue, Gregory P.
BookMark eNp1ks1v1DAQxSNUREvpmaslLlxC_RUnviCV5atSCxVtV9ysiTNZvGTtxU5WQvzzeNlFoivhiy3Pe79nj-ZpceSDx6J4zugrITQ934C1zmPSjDEh60fFCae1KoUWX4_-OR8XZyktaV6aiUbVT4pjIRtR8bo5KX69xQ0OYb1CP5LQEyC3F19uy1mYl5zMdwFkBr5zHYxI7pPzC3IzgB_LN5CwI9fgpx7sOMVtJQsz4i602RnIdUjgLJm7OKVycN-RfAIfyhuIo7MDPise9zAkPNvvp8X9-3d3s4_l1ecPl7OLq9JKJcey6tsKu962rBWItlaATPAeaM8kdgo0o9hxQTslqcXOCtvyXNJaaewVR3FaXO64XYClWUe3gvjTBHDmz0WIC7N_kZGiVczyutISpEVsWg21YgwUr2yFTWa93rHWU7vKYbltEYYH0IcV776ZRdiYRjFN9Rbwcg-I4ceEaTQrlywOuaUYpmS4opIyoRuWpS8OpMswRZ9btVVxzmquqqyqdiobQ0oRe2PdCKML23w3GEbNdlrMwbRk3_mB7-8n_uf4DVZbxaU
CitedBy_id crossref_primary_10_3390_bioengineering10020148
crossref_primary_10_1039_D4NR05354K
crossref_primary_10_1016_j_cropd_2023_100028
crossref_primary_10_3389_fpls_2022_963756
crossref_primary_10_3389_fpls_2023_1202570
crossref_primary_10_3390_vaccines12010037
crossref_primary_10_1007_s40259_022_00544_8
crossref_primary_10_3389_fpls_2023_1325162
crossref_primary_10_1371_journal_pone_0277668
crossref_primary_10_1111_pbi_13908
crossref_primary_10_3389_fpls_2022_995429
crossref_primary_10_1021_jacs_2c09160
crossref_primary_10_1002_bip_23563
crossref_primary_10_3390_life13030617
crossref_primary_10_3390_biology12070983
crossref_primary_10_1136_bmj_q1153
crossref_primary_10_3389_fbioe_2022_867119
crossref_primary_10_3390_vaccines11081347
crossref_primary_10_3390_ijms252211979
crossref_primary_10_1134_S1021443724607778
crossref_primary_10_31857_S0026898424030047
crossref_primary_10_3390_ijms24021701
crossref_primary_10_1016_j_hlife_2024_09_002
crossref_primary_10_1128_iai_00019_24
crossref_primary_10_1186_s12951_022_01469_8
crossref_primary_10_1016_j_heliyon_2024_e37634
crossref_primary_10_31857_S0015330324050045
crossref_primary_10_3389_fimmu_2024_1392898
crossref_primary_10_3389_fpls_2023_1146234
crossref_primary_10_3390_plants11243425
crossref_primary_10_1016_j_colsurfb_2024_114251
crossref_primary_10_1080_21645515_2022_2087412
crossref_primary_10_3389_fpls_2023_1290042
crossref_primary_10_3390_ijms232415684
crossref_primary_10_3390_vaccines9111346
crossref_primary_10_1007_s12257_022_0107_8
crossref_primary_10_1016_j_virol_2022_11_004
crossref_primary_10_1021_acsnano_2c06143
crossref_primary_10_1021_acsanm_3c00787
crossref_primary_10_1016_j_trechm_2024_06_004
crossref_primary_10_3390_vaccines12050448
crossref_primary_10_1016_j_ejmech_2023_116000
crossref_primary_10_1134_S0026893324700043
crossref_primary_10_1002_cbic_202200040
crossref_primary_10_1038_s42003_024_06982_0
crossref_primary_10_3390_vaccines11081372
crossref_primary_10_1002_agt2_274
crossref_primary_10_3390_plants11081093
Cites_doi 10.1016/j.cell.2019.01.046
10.1016/S1473-3099(10)70262-0
10.1038/nri1732
10.1016/j.vaccine.2006.06.003
10.1038/s41579-020-00468-6
10.3389/fmicb.2018.01195
10.1038/s41586-020-2798-3
10.4161/hv.27567
10.1038/s41423-020-0400-4
10.1101/2020.04.20.051219
10.1002/adma.202005637
10.1371/annotation/3b62fdef-4cdd-40cc-b69d-69afd2000c4f
10.1038/s41586-021-03365-x
10.1016/j.cell.2020.10.043
10.1016/j.vaccine.2006.04.058
10.1016/j.cell.2020.06.025
10.1007/s00281-017-0629-x
10.3389/fimmu.2019.01722
10.1021/bc060124m
10.1016/j.vaccine.2016.09.063
10.1016/S0140-6736(20)32014-6
10.1128/JVI.79.17.11335-11342.2005
10.3389/fimmu.2019.00736
10.1002/wnan.1447
10.1038/srep00124
10.1038/s41467-020-16256-y
10.1021/acsnano.8b02805
10.1016/j.vaccine.2006.08.011
10.1007/s12250-018-0009-2
10.1038/s41591-021-01370-1
10.1002/jcp.28120
10.1016/j.vaccine.2014.04.051
10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492
10.1126/science.abc2241
10.3389/fcimb.2013.00013
10.1016/j.smim.2017.08.014
10.1128/JVI.00671-11
10.1016/j.virol.2005.12.039
10.1371/journal.pone.0130858
10.1016/j.virol.2009.07.018
10.1586/14760584.7.1.33
10.1126/science.abc5902
10.1038/s41577-020-00434-6
10.1016/j.vaccine.2006.10.031
10.1016/S0065-2776(07)96002-2
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7T7
7XB
8FD
8FE
8FH
8FK
8G5
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
C1K
CCPQU
COVID
DWQXO
FR3
GNUQQ
GUQSH
HCIFZ
LK8
M2O
M7P
MBDVC
P64
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/vaccines9111347
DatabaseName CrossRef
ProQuest Central (Corporate)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (purchase pre-March 2016)
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Engineering Research Database
ProQuest Central Student
Research Library Prep
SciTech Premium Collection
Biological Sciences
Research Library
Biological Science Database
Research Library (Corporate)
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals - May need to register for free articles
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Research Library
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
Biotechnology and BioEngineering Abstracts
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic

CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 2076-393X
ExternalDocumentID oai_doaj_org_article_43b61c27594a4cee8b9a7611a625c5e8
PMC8619098
10_3390_vaccines9111347
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID 53G
5VS
8FE
8FH
8G5
AADQD
AAHBH
AAYXX
ABUWG
ADBBV
AEUYN
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
GNUQQ
GROUPED_DOAJ
GUQSH
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
3V.
7T7
7XB
8FD
8FK
C1K
COVID
FR3
MBDVC
P64
PKEHL
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c464t-5fb5edfcb1b3eec76ae132fa0f14ed6a910ed230d640cedc3cb2f149969ef62e3
IEDL.DBID M48
ISSN 2076-393X
IngestDate Wed Aug 27 01:29:44 EDT 2025
Thu Aug 21 18:01:30 EDT 2025
Mon Jul 21 10:26:44 EDT 2025
Fri Jul 25 11:01:01 EDT 2025
Tue Jul 01 02:25:01 EDT 2025
Thu Apr 24 22:58:33 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c464t-5fb5edfcb1b3eec76ae132fa0f14ed6a910ed230d640cedc3cb2f149969ef62e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-4397-7132
0000-0003-1085-0319
0000-0002-4243-2667
0000-0001-7718-1522
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/vaccines9111347
PMID 34835278
PQID 2602217265
PQPubID 2032320
ParticipantIDs doaj_primary_oai_doaj_org_article_43b61c27594a4cee8b9a7611a625c5e8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8619098
proquest_miscellaneous_2604013981
proquest_journals_2602217265
crossref_citationtrail_10_3390_vaccines9111347
crossref_primary_10_3390_vaccines9111347
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20211117
PublicationDateYYYYMMDD 2021-11-17
PublicationDate_xml – month: 11
  year: 2021
  text: 20211117
  day: 17
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Vaccines (Basel)
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Ward (ref_38) 2021; 27
Krueger (ref_44) 2019; 10
Wu (ref_37) 2020; 368
Barnes (ref_45) 2020; 182
Andreano (ref_4) 2019; 10
Kemnade (ref_16) 2014; 32
Krammer (ref_5) 2020; 586
ref_19
Bruun (ref_11) 2018; 12
Gregory (ref_6) 2013; 3
Wang (ref_47) 2020; 11
Palmer (ref_23) 2006; 24
Jeyanathan (ref_48) 2020; 20
Mekhaiel (ref_36) 2011; 1
Walls (ref_39) 2020; 183
ref_25
Cole (ref_49) 2005; 302
Mohsen (ref_8) 2017; 34
Olotu (ref_42) 2011; 11
Channappanavar (ref_32) 2017; 39
Steele (ref_12) 2017; 9
Brouwer (ref_46) 2020; 369
Ward (ref_14) 2020; 396
McCormick (ref_15) 2008; 7
Darroudi (ref_7) 2019; 234
Pewe (ref_31) 2005; 79
Arnaboldi (ref_20) 2016; 34
Mallajosyula (ref_21) 2014; 10
Mansour (ref_22) 2018; 9
Jaume (ref_27) 2011; 85
ref_33
McCormick (ref_13) 2006; 17
Jaume (ref_28) 2012; 18
Perlman (ref_30) 2005; 5
Du (ref_35) 2007; 25
Kratzel (ref_1) 2021; 19
Marcandalli (ref_9) 2019; 176
McCormick (ref_17) 2006; 24
Smith (ref_18) 2006; 348
Du (ref_34) 2009; 393
ref_43
Tai (ref_24) 2020; 17
Petrosillo (ref_2) 2020; 26
Luo (ref_29) 2018; 33
ref_40
Schoenborn (ref_50) 2007; 96
ref_3
Ellis (ref_10) 2021; 592
Kam (ref_26) 2007; 25
Huang (ref_41) 2020; 32
References_xml – volume: 176
  start-page: 1420
  year: 2019
  ident: ref_9
  article-title: Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus
  publication-title: Cell
  doi: 10.1016/j.cell.2019.01.046
– volume: 11
  start-page: 102
  year: 2011
  ident: ref_42
  article-title: Efficacy of RTS,S/AS01E Malaria Vaccine and Exploratory Analysis on Anti-Circumsporozoite Antibody Titres and Protection in Children Aged 5-17 Months in Kenya and Tanzania: A Randomised Controlled Trial
  publication-title: Lancet Infect. Dis.
  doi: 10.1016/S1473-3099(10)70262-0
– volume: 5
  start-page: 917
  year: 2005
  ident: ref_30
  article-title: Immunopathogenesis of Coronavirus Infections: Implications for SARS
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri1732
– volume: 24
  start-page: 6414
  year: 2006
  ident: ref_17
  article-title: TMV-Peptide Fusion Vaccines Induce Cell-Mediated Immune Responses and Tumor Protection in Two Murine Models
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.06.003
– volume: 302
  start-page: 191
  year: 2005
  ident: ref_49
  article-title: Interferon-Gamma ELISPOT Assay for the Quantitative Measurement of Antigen-Specific Murine CD8+ T-Cells
  publication-title: Methods Mol. Biol.
– volume: 19
  start-page: 155
  year: 2021
  ident: ref_1
  article-title: Coronavirus Biology and Replication: Implications for SARS-CoV-2
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/s41579-020-00468-6
– volume: 9
  start-page: 1195
  year: 2018
  ident: ref_22
  article-title: An Improved Tobacco Mosaic Virus (TMV)-Conjugated Multiantigen Subunit Vaccine Against Respiratory Tularemia
  publication-title: Front. Microbiol.
  doi: 10.3389/fmicb.2018.01195
– volume: 586
  start-page: 516
  year: 2020
  ident: ref_5
  article-title: SARS-CoV-2 Vaccines in Development
  publication-title: Nature
  doi: 10.1038/s41586-020-2798-3
– volume: 10
  start-page: 586
  year: 2014
  ident: ref_21
  article-title: Single-Dose Monomeric HA Subunit Vaccine Generates Full Protection from Influenza Challenge
  publication-title: Hum. Vaccines Immunother.
  doi: 10.4161/hv.27567
– volume: 17
  start-page: 613
  year: 2020
  ident: ref_24
  article-title: Characterization of the Receptor-Binding Domain (RBD) of 2019 Novel Coronavirus: Implication for Development of RBD Protein as a Viral Attachment Inhibitor and Vaccine
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/s41423-020-0400-4
– ident: ref_25
  doi: 10.1101/2020.04.20.051219
– volume: 32
  start-page: e2005637
  year: 2020
  ident: ref_41
  article-title: SARS-CoV-2 RBD Neutralizing Antibody Induction Is Enhanced by Particulate Vaccination
  publication-title: Adv. Mater. Deerfield Beach Fla
  doi: 10.1002/adma.202005637
– ident: ref_43
  doi: 10.1371/annotation/3b62fdef-4cdd-40cc-b69d-69afd2000c4f
– volume: 592
  start-page: 623
  year: 2021
  ident: ref_10
  article-title: Quadrivalent Influenza Nanoparticle Vaccines Induce Broad Protection
  publication-title: Nature
  doi: 10.1038/s41586-021-03365-x
– volume: 183
  start-page: 1367
  year: 2020
  ident: ref_39
  article-title: Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
  publication-title: Cell
  doi: 10.1016/j.cell.2020.10.043
– volume: 24
  start-page: 5516
  year: 2006
  ident: ref_23
  article-title: Protection of Rabbits against Cutaneous Papillomavirus Infection Using Recombinant Tobacco Mosaic Virus Containing L2 Capsid Epitopes
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.04.058
– volume: 182
  start-page: 828
  year: 2020
  ident: ref_45
  article-title: Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
  publication-title: Cell
  doi: 10.1016/j.cell.2020.06.025
– volume: 26
  start-page: 729
  year: 2020
  ident: ref_2
  article-title: COVID-19, SARS and MERS: Are They Closely Related?
  publication-title: Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis.
– volume: 39
  start-page: 529
  year: 2017
  ident: ref_32
  article-title: Pathogenic Human Coronavirus Infections: Causes and Consequences of Cytokine Storm and Immunopathology
  publication-title: Semin. Immunopathol.
  doi: 10.1007/s00281-017-0629-x
– volume: 10
  start-page: 1722
  year: 2019
  ident: ref_4
  article-title: Vaccine Evolution and Its Application to Fight Modern Threats
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.01722
– volume: 17
  start-page: 1330
  year: 2006
  ident: ref_13
  article-title: Chemical Conjugate TMV-Peptide Bivalent Fusion Vaccines Improve Cellular Immunity and Tumor Protection
  publication-title: Bioconjug. Chem.
  doi: 10.1021/bc060124m
– volume: 34
  start-page: 5768
  year: 2016
  ident: ref_20
  article-title: Intranasal Delivery of a Protein Subunit Vaccine Using a Tobacco Mosaic Virus Platform Protects against Pneumonic Plague
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2016.09.063
– volume: 396
  start-page: 1491
  year: 2020
  ident: ref_14
  article-title: Efficacy, Immunogenicity, and Safety of a Plant-Derived, Quadrivalent, Virus-like Particle Influenza Vaccine in Adults (18-64 Years) and Older Adults (≥65 Years): Two Multicentre, Randomised Phase 3 Trials
  publication-title: Lancet Lond. Engl.
  doi: 10.1016/S0140-6736(20)32014-6
– volume: 79
  start-page: 11335
  year: 2005
  ident: ref_31
  article-title: A Severe Acute Respiratory Syndrome-Associated Coronavirus-Specific Protein Enhances Virulence of an Attenuated Murine Coronavirus
  publication-title: J. Virol.
  doi: 10.1128/JVI.79.17.11335-11342.2005
– volume: 10
  start-page: 736
  year: 2019
  ident: ref_44
  article-title: RNA and Toll-Like Receptor 7 License the Generation of Superior Secondary Plasma Cells at Multiple Levels in a B Cell Intrinsic Fashion
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00736
– volume: 9
  start-page: e1447
  year: 2017
  ident: ref_12
  article-title: Synthetic Plant Virology for Nanobiotechnology and Nanomedicine
  publication-title: Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.
  doi: 10.1002/wnan.1447
– volume: 1
  start-page: 124
  year: 2011
  ident: ref_36
  article-title: Polymeric Human Fc-Fusion Proteins with Modified Effector Functions
  publication-title: Sci. Rep.
  doi: 10.1038/srep00124
– volume: 11
  start-page: 2251
  year: 2020
  ident: ref_47
  article-title: A Human Monoclonal Antibody Blocking SARS-CoV-2 Infection
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-16256-y
– volume: 18
  start-page: 31
  year: 2012
  ident: ref_28
  article-title: SARS CoV Subunit Vaccine: Antibody-Mediated Neutralisation and Enhancement
  publication-title: Hong Kong Med. J.
– ident: ref_3
– volume: 12
  start-page: 8855
  year: 2018
  ident: ref_11
  article-title: Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination
  publication-title: ACS Nano
  doi: 10.1021/acsnano.8b02805
– volume: 25
  start-page: 729
  year: 2007
  ident: ref_26
  article-title: Antibodies against Trimeric S Glycoprotein Protect Hamsters against SARS-CoV Challenge despite Their Capacity to Mediate FcgammaRII-Dependent Entry into B Cells in Vitro
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.08.011
– volume: 33
  start-page: 201
  year: 2018
  ident: ref_29
  article-title: Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized with an Inactivated SARS-CoV Vaccine
  publication-title: Virol. Sin.
  doi: 10.1007/s12250-018-0009-2
– volume: 27
  start-page: 1071
  year: 2021
  ident: ref_38
  article-title: Phase 1 Randomized Trial of a Plant-Derived Virus-like Particle Vaccine for COVID-19
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01370-1
– volume: 234
  start-page: 12530
  year: 2019
  ident: ref_7
  article-title: Nanovaccine: A Novel Approach in Immunization
  publication-title: J. Cell. Physiol.
  doi: 10.1002/jcp.28120
– ident: ref_40
– volume: 32
  start-page: 4228
  year: 2014
  ident: ref_16
  article-title: Tobacco Mosaic Virus Efficiently Targets DC Uptake, Activation and Antigen-Specific T Cell Responses in Vivo
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2014.04.051
– ident: ref_33
  doi: 10.1371/annotation/2965cfae-b77d-4014-8b7b-236e01a35492
– volume: 368
  start-page: 1274
  year: 2020
  ident: ref_37
  article-title: A Noncompeting Pair of Human Neutralizing Antibodies Block COVID-19 Virus Binding to Its Receptor ACE2
  publication-title: Science
  doi: 10.1126/science.abc2241
– volume: 3
  start-page: 13
  year: 2013
  ident: ref_6
  article-title: Vaccine Delivery Using Nanoparticles
  publication-title: Front. Cell. Infect. Microbiol.
  doi: 10.3389/fcimb.2013.00013
– volume: 34
  start-page: 123
  year: 2017
  ident: ref_8
  article-title: Major Findings and Recent Advances in Virus-like Particle (VLP)-Based Vaccines
  publication-title: Semin. Immunol.
  doi: 10.1016/j.smim.2017.08.014
– volume: 85
  start-page: 10582
  year: 2011
  ident: ref_27
  article-title: Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a PH- and Cysteine Protease-Independent FcγR Pathway
  publication-title: J. Virol.
  doi: 10.1128/JVI.00671-11
– volume: 348
  start-page: 475
  year: 2006
  ident: ref_18
  article-title: Modified Tobacco Mosaic Virus Particles as Scaffolds for Display of Protein Antigens for Vaccine Applications
  publication-title: Virology
  doi: 10.1016/j.virol.2005.12.039
– ident: ref_19
  doi: 10.1371/journal.pone.0130858
– volume: 393
  start-page: 144
  year: 2009
  ident: ref_34
  article-title: Recombinant Receptor-Binding Domain of SARS-CoV Spike Protein Expressed in Mammalian, Insect and E. Coli Cells Elicits Potent Neutralizing Antibody and Protective Immunity
  publication-title: Virology
  doi: 10.1016/j.virol.2009.07.018
– volume: 7
  start-page: 33
  year: 2008
  ident: ref_15
  article-title: Genetically Engineered Tobacco Mosaic Virus as Nanoparticle Vaccines
  publication-title: Expert Rev. Vaccines
  doi: 10.1586/14760584.7.1.33
– volume: 369
  start-page: 643
  year: 2020
  ident: ref_46
  article-title: Potent Neutralizing Antibodies from COVID-19 Patients Define Multiple Targets of Vulnerability
  publication-title: Science
  doi: 10.1126/science.abc5902
– volume: 20
  start-page: 615
  year: 2020
  ident: ref_48
  article-title: Immunological Considerations for COVID-19 Vaccine Strategies
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/s41577-020-00434-6
– volume: 25
  start-page: 2832
  year: 2007
  ident: ref_35
  article-title: Receptor-Binding Domain of SARS-CoV Spike Protein Induces Long-Term Protective Immunity in an Animal Model
  publication-title: Vaccine
  doi: 10.1016/j.vaccine.2006.10.031
– volume: 96
  start-page: 41
  year: 2007
  ident: ref_50
  article-title: Regulation of Interferon-Gamma during Innate and Adaptive Immune Responses
  publication-title: Adv. Immunol.
  doi: 10.1016/S0065-2776(07)96002-2
SSID ssj0000913867
Score 2.4167645
Snippet Stable, effective, easy-to-manufacture vaccines are critical to stopping the COVID-19 pandemic resulting from the coronavirus SARS-CoV-2. We constructed a...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 1347
SubjectTerms ACE2
Angiotensin-converting enzyme 2
Antigens
Binding
Chromatography
Coronaviruses
COVID-19
COVID-19 vaccines
CpG islands
Disease transmission
Epitopes
Fatalities
Glycoproteins
Humidity
Immunogenicity
Immunoglobulin G
Infections
Influenza
Lymphocytes T
Manufacturing
Monoclonal antibodies
nanoparticle
Nanoparticles
Neutralizing
Pandemics
Pathogens
Peptides
plant-based manufacturing
Proteins
receptor-binding domain
Receptors
Respiratory diseases
SARS-CoV-2 vaccine
Severe acute respiratory syndrome coronavirus 2
Spike glycoprotein
Spike protein
Tobacco
Transmission electron microscopy
Vaccines
Viral diseases
Viruses
SummonAdditionalLinks – databaseName: Directory of Open Access Journals - May need to register for free articles
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15Kn9RtWlQooYeosS1Zso_J0hAKW5Zms-Rm9KRLg13i3ULIn8-M7GzsQumlV0s28mhGMx-a-YaQj8oVmefasaBsyoQqU6ZzLpgR0gnlwelrBIrzb_LsQny9LC5Hrb4wJ6ynB-4FdyS4kZnNVVEJLeBEL02lAXpnGgJ3W_hY5gs-bwSm4hlcZbyUqufy4YDrj35rizfVHRo3x2YqIzcU2fonIeY0QXLkcU6fkidDqEiP-yU-I49885wcLHqu6ZtDunwoneoO6QFdPLBQ37wgt6N0INoGqun58fdzNmtXLKerfpl0hkUtiPlpTB2g2MJow07Aszk6180Wyx5iHSOFifCJJVi_tS2dt51eW7paX287drX-6Smc0i1bDOJ8SS5OvyxnZ2zotMCskGLDimAK74I1meHeWyW1B5QadBoy4Z3UEFN4B2DFSZFaEAu3JochwEqVDzL3_BXZa9rGvya0ghhGKIM3wJWoONcBYjzHXeDeuqwICfl8L_jaDjTk2A3jqgY4gjtV_7FTCfm0e-FXz8Dx96knuJO7aUidHR-AQtWDBOp_KVRC9u_1oB7suasB9eXYyksWCfmwGwZLxOsV3fh2G-cgWK3KLCFqoj-TBU1HmvWPyOldApBNq_LN__iDt-Rxjpk3mKyo9sne5nrr30HotDHvo5XcAT7HGvQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZge-GCykuEFmQkVHGoaRI7dnJC3VWrCrHVqt2ueoscP8oKlJTNLlLFn2cmyT6CBNfYSSzb8_g8428I-aBsEjmuLfPKhEyoNGQ65oIVQlqhHBh9jUBxfCkvbsSX2-S2O3Cru7TKtU5sFLWtDJ6Rn4DfHWMxJZl8vv_JsGoURle7EhqPyR6o4DQdkL3h2eXkanPKgqyXqVQtpw8HfH_ySxuMWNco5ByLquyYo4a1v-dq9hMldyzP-T552rmM9LRd42fkkSufk6NJyzn9cEyn2ytU9TE9opMtG_XDC_J7Jy2IVp5qen16dc1G1YzFdNYOk47wcgtif9qkEFAsZbRkQ7Bwlo51ucLrD819Rgod4RNT0ALGVHRc1Xpu6Gy-WNXs6_y7o6CtKzbp9uNLcnN-Nh1dsK7iAjNCiiVLfJE4600RFdw5o6R2gFa9Dn0knJUafAtnAbRYKUID08JNEUMTYKbMeRk7_ooMyqp0rwnNwJcRqsBIcCYyzrUHX89y67kzNkp8QD6tJz43HR05VsX4kQMswZXK_1qpgHzcvHDfMnH8u-sQV3LTDSm0mwfV4i7vZiAXvJCRiVWSCS3AVUiLTCsZRRoQoUlcGpDD9T7IO7mu8-0uDMj7TTNIJIZZdOmqVdMHQWuWRgFRvf3TG1C_pZx_a7i9UwC0YZa--f_PD8iTGHNrMB1RHZLBcrFyb8E5WhbvOgn4A8CBE-g
  priority: 102
  providerName: ProQuest
Title Development of a SARS-CoV-2 Vaccine Candidate Using Plant-Based Manufacturing and a Tobacco Mosaic Virus-like Nano-Particle
URI https://www.proquest.com/docview/2602217265
https://www.proquest.com/docview/2604013981
https://pubmed.ncbi.nlm.nih.gov/PMC8619098
https://doaj.org/article/43b61c27594a4cee8b9a7611a625c5e8
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Nb9MwFLdgu3BBfIrAqIyEJg7zSGLHjg8IrdWmCalTtbVVb5FjO6OiSqBpERX_PM9O2i5oSFxjx0reh9_72e8DoffCJJGlypBC6JAwkYZExZSRnHHDhAWjrxxQHF7xywn7Mktm-3ZALQHre6Gd6yc1WS5Of_3YfAaF_-QQJ0D2jz-VdpfQtdNbysRDdAhmSbh2BsPW1_fbsoxo6jvKxoDdCZV01pT6uW-NjpXyxfw7Hmg3fvKOQbp4gh63niQ-a1j_FD2w5TN0PGpKUW9O8HifWVWf4GM82hep3jxHv-9EC-GqwArfnF3fkEE1JTGeNp-JBy7nxR0JYB9ZgF2HoxXpg-EzeKjKtcuK8GmOGCbCEmPYHLSu8LCq1Vzj6Xy5rsli_s1i2MQrMmrF9AWaXJyPB5ekbcRANONsRZIiT6wpdB7l1FotuLIAYgsVFhGzhitwOawBLGM4CzWQheo8hiGAUtIWPLb0JTooq9K-QliCi8NE7i6IJZOUqgJcQENNQa02UVIE6HRL-Ey3Vcpds4xFBmjFcSr7i1MB-rB74XtToOPfU_uOk7tprrK2f1Atb7OWAhmjOY90LBLJFAMPIs2lEjyKFABFndg0QEdbOci20poBKIxdpy-eBOjdbhgU1d2-qNJWaz_HYVmZRgESHfnpfFB3pJx_9SW_U8C5oUxf___PvkGPYhd-4yIWxRE6WC3X9i34T6u8hw7751ej654_f-h5LfkDehAfew
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdG9wAviE9RGGAkmHiYWRI7TvKA0Fo2daytqq2r9pY5trNVoGQ0Lajif-Jv5C5Jv5Dgba-xk1i-893vfF-EvA2M71quDEsD7TARhA5THhcsEdKIwILSV2go9vqycy6-XPgXW-T3IhcGwyoXMrEU1CbXeEe-D7jbw2ZK0v90851h1yj0ri5aaFRscWLnP8FkKz4efwb6vvO8o8Nhu8PqrgJMCymmzE8T35pUJ27CrdWBVBYsslQ5qSuskQr0pzUAzI0UjrZGc514MAR2QWRT6VkO371DtgWHBTXIduuwPzhd3upglc1QBlUNIc4jZ_-H0ughL1CocGzisqb-yi4BG9B2MzBzTdMdPSD3a4hKDyqeeki2bPaI7A6qGtfzPTpcpWwVe3SXDlbVr-ePya-1MCSap1TRs4PTM9bOR8yjo2qZtI3JNHjXQMuQBYqtk6asBRrV0J7KZphuUeZPUpgInxiC1NE6p728UGNNR-PJrGDd8VdLQTvkbFDz_xNyfiu0eEoaWZ7ZZ4RGgJ1EkKDnORIR5yoFbGm4SbnVxvXTJvmw2PhY1-XPsQvHtxjMIKRU_BelmuT98oWbqvLHv6e2kJLLaViyu3yQT67iegdiwRPpai_wI6EEQJMwiVQgXVeBBap9GzbJzoIP4lqOFPGK65vkzXIYJAC6dVRm81k5B43kKHSbJNjgn40FbY5k4-uylngIBrQThc____PX5G5n2OvG3eP-yQtyz8O4HgyFDHZIYzqZ2ZcAzKbJq_o0UHJ52wfwD9ovU3M
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLZGJyFeEFdRNsBIMPEw0yR24uQBobVbtbG1qrau2ltwbIdVoGQ0Lajin_HrOCdJb0jwttfYcSIfn8vncyPkjTS-a7kyLJXaYUKGDlMeFywRgRHSgtJXCBR7_eD4Uny68q-2yO9FLgyGVS5kYimoTa7xjrwFdreHzZQCv5XWYRGDw-7Hm-8MO0ihp3XRTqM6Iqd2_hPgW_Hh5BBo_dbzukfDzjGrOwwwLQIxZX6a-NakOnETbq2WgbKAzlLlpK6wJlCgS60BI90EwtHWaK4TD4YAI0Q2DTzLYd07ZFsiKmqQ7fZRf3C-vOHBipthIKt6QpxHTuuH0ugtL1DAcGzosqYKy44BG2buZpDmmtbrPiD3a3OVHlTn6yHZstkjsjeo6l3P9-lwlb5V7NM9OlhVwp4_Jr_WQpJonlJFLw7OL1gnHzGPjqrfpB1MrMF7B1qGL1BsozRlbdCuhvZUNsPUizKXksJEWGIIEkjrnPbyQo01HY0ns4Kdjb9aCpoiZ4OaF56Qy1uhxVPSyPLMPiM0AjtKyAS90JGIOFcp2JmGm5RbbVw_bZL3i42PdV0KHTtyfIsBEiGl4r8o1STvli_cVFVA_j21jZRcTsPy3eWDfPIlrncgFjwJXO1JPxJKgJkSJpGSgesqQKPat2GT7C7OQVzLlCJecUCTvF4OgzRAF4_KbD4r5yBgjkK3SeTG-dn4oc2RbHxd1hUPAUw7Ufj8_x9_Re4C48VnJ_3THXLPwxAfjIqUu6QxnczsC7DRpsnLmhko-Xzb_PcHNH1XqA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+SARS-CoV-2+Vaccine+Candidate+Using+Plant-Based+Manufacturing+and+a+Tobacco+Mosaic+Virus-like+Nano-Particle&rft.jtitle=Vaccines+%28Basel%29&rft.au=Royal%2C+Joshua+M.&rft.au=Simpson%2C+Carrie+A.&rft.au=McCormick%2C+Alison+A.&rft.au=Phillips%2C+Amanda&rft.date=2021-11-17&rft.issn=2076-393X&rft.eissn=2076-393X&rft.volume=9&rft.issue=11&rft.spage=1347&rft_id=info:doi/10.3390%2Fvaccines9111347&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_vaccines9111347
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2076-393X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2076-393X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2076-393X&client=summon